AdaptHealth earnings release, August 4, 2026

AdaptHealth Corp. (AHCO) · Form 8-K, Item 2.02 · Filed · SEC filing

ADAPTHEALTH CORP. ANNOUNCES SECOND QUARTER 2026 RESULTS

CONSHOHOCKEN, Pa. – August 4, 2026 - AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2026.

Second Quarter Business Highlights

• Completed its first full quarter under the Company's exclusive capitated agreement with a large national integrated delivery network, with the contract now fully at run-rate.

• Signed a new capitated agreement with Humana OneHome in South Florida and Texas and successfully completed the transition of approximately 478,000 members.

• Subsequent to quarter-end, entered into a definitive agreement to sell the Company's Diabetes Health business for $235.0 million in cash, subject to customary purchase price adjustments, the most significant step yet in AdaptHealth's multi-year effort to concentrate its portfolio around its core Sleep Health, Respiratory Health, and supporting Wellness-at-Home businesses. The Diabetes Health business will now be presented as discontinued operations.

• Subsequent to quarter end, entered into a joint venture that combines the Company's eCommerce asset with a leading eCommerce sleep retailer and adds a home sleep test capability to help reach the vast undiagnosed OSA population.

• Grew registered myAPP users to more than 512,000, up 56% from year end 2025 and launched an AI-powered mask-fitting tool, advancing patient digital engagement and expanding self-service capabilities.

• Subsequent to quarter-end, redeemed the Company’s 6.125% Senior Notes due 2028 with the proceeds from the $325 million delayed draw term loan secured as part of the April 2026 refinancing.

• Completed a workforce restructuring, generating $19 million in annualized savings while maintaining full operational delivery across all functions.

Second Quarter Results

All comparisons are to the quarter ended June 30, 2025 unless otherwise stated. The amounts presented below reflect the Company’s continuing operations, except for cash flow from operations and free cash flow, which includes the cash flows from continuing operations and discontinued operations, see below for further discussion.

• Net revenue was $740.3 million compared to $657.1 million, an increase of 12.7%.

• Organic revenue growth of 15.9%, with growth across each of the Company’s reportable segments.

• Net loss attributable to AdaptHealth Corp. was $145.3 million compared to net income of $4.2 million, largely resulting from a $144.2 million pre-tax write down of goodwill.

• Adjusted EBITDA was $132.0 million compared to $136.4 million, a decrease of 3.2%.

• Cash flow from operations was $239.0 million year-to-date 2026, a decrease from $257.5 million during the comparable period in 2025, and free cash flow was negative $48.4 million year-to-date 2026, compared to $73.3 million during the comparable period in 2025.

-1 -

Management Commentary

“In the second quarter, we delivered 15.9% organic growth, with record volume gains across the business," said Suzanne Foster, Chief Executive Officer. "Also, in July we signed a definitive agreement to divest our Diabetes Health business, the most significant step yet in our multi-year effort to focus AdaptHealth on our core Sleep Health, Respiratory Health, and supporting Wellness-at-Home businesses. Our West Coast capitated partnership reached full scale in the quarter, and the complexity of that transition has impacted our margins. Together with an unexpected price increase from one of our manufacturers, this has led us to lower our full-year outlook. We are moving quickly to address the cost pressures introduced by our rapid growth, and we believe these actions will make us a stronger, more efficient company."

Financial Outlook

The Company is revising its financial guidance for fiscal year 2026 on a continuing operations basis, which excludes the Diabetes Health business, except for free cash flow, which includes the cash flows from continuing operations and discontinued operations, as follows:

• Net revenue of $2.85 billion to $2.89 billion

• Adjusted EBITDA of $490 million to $520 million

• Free cash flow of $80 million to $120 million

Relative to our prior fiscal year 2026 Adjusted EBITDA guidance of $680 million to $730 million, the revised guidance includes a $100 million impact from reporting the Diabetes Health business as discontinued operations, including $60 million of previously allocated corporate overhead that will remain in continuing operations, of which the Company expects roughly half to be eliminated within 12 months thereafter. The revised guidance also includes a $55 million impact related to our West Coast capitated contract; a $30 million impact from a manufacturer price increase; and a $15 million impact from other portfolio actions.

Conference Call

Management will host a teleconference today, Tuesday, August 4, 2026, at 8:30 am ET to discuss the results and business activities with analysts and investors.

Interested parties may participate in the call by dialing:

• 800-274-8461 (Domestic) or

• 203-518-9814 (International)

When prompted, reference Conference ID:

AHCO2Q26

To access the Webcast, please go to the Company’s Investor Relations page at https://adapthealth.com/investorrelations/

Following the live call, a replay will be available for six months on the Company's website, www.adapthealth.com, under "Investor Relations."

About AdaptHealth Corp.... (truncated)nt provides sleep therapy equipment, supplies and related services (including CPAP and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Wellness at Home segment provides home medical equipment and services to patients in their homes including those who have been discharged from acute care and other facilities. The segment tailors a service model to patients who are adjusting to new lifestyles or navigating complex disease states by providing essential medical supplies and durable medical equipment.

-2 -

In July 2026, AdaptHealth entered into a definitive agreement to sell the Diabetes Health business for $235.0 million in cash, subject to customary purchase price adjustments. As a result of this transaction, the Diabetes Health business met the criteria to be reported as discontinued operations. Therefore, AdaptHealth has reported the results of the Diabetes Health business, including the results of operations, and related assets and liabilities, as discontinued operations for all periods presented herein.

The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid, and commercial insurance payors, reaching approximately 4.8 million patients annually in all 50 states through its network of approximately 670 locations in 48 states.

Financial statements

Income Statement

Three Months Ended — Consolidated Statements of Operations (Unaudited) (in thousands, except per share data)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Net revenue740,307657,1001,420,1801,301,647
Costs and expenses:Cost of net revenue636,101521,3121,220,3421,060,281
Costs and expenses:General and administrative expenses96,09395,263189,977180,158
Costs and expenses:Depreciation and amortization, excluding patient equipment depreciation7,9487,05615,11714,328
Costs and expenses:Goodwill impairment144,236144,236
Costs and expenses:Total costs and expenses884,378623,6311,569,6721,254,767
Costs and expenses:Gain on sale of businesses-6,269-32,225-6,269-32,225
Costs and expenses:Operating (loss) income-137,80265,694-143,22379,105
Costs and expenses:Interest expense, net26,20927,53351,80355,932
Costs and expenses:Loss on extinguishment of debt1,3221,322
Costs and expenses:(Loss) income from continuing operations before income taxes-165,33338,161-196,34823,173
Costs and expenses:Income tax (benefit) expense-21,22732,780-28,39230,294
Costs and expenses:Net (loss) income from continuing operations-144,1065,381-167,956-7,121
Costs and expenses:Net income from discontinued operations, net of tax11,38710,44720,36416,870
Costs and expenses:Net (loss) income-132,71915,828-147,5929,749
Costs and expenses:Income attributable to noncontrolling interest1,2101,1542,3772,282
Costs and expenses:Net (loss) income attributable to AdaptHealth Corp.-133,92914,674-149,9697,467
Costs and expenses:Weighted average common shares outstanding - basic136,120134,993135,950134,897
Costs and expenses:Weighted average common shares outstanding - diluted136,120137,071135,950134,897
Basic net (loss) income per share:Continuing operations-1.070.03-1.25-0.06
Basic net (loss) income per share:Discontinued operations0.080.070.150.11
Basic net (loss) income per share:Basic net (loss) income per share-0.990.1-1.10.05
Diluted net (loss) income per share:Continuing operations-1.070.03-1.25-0.06
Diluted net (loss) income per share:Discontinued operations0.080.070.150.11
Diluted net (loss) income per share:Diluted net (loss) income per share-0.990.1-1.10.05

Income Statement

Three Months Ended June 30, (in thousands, except percentages)

Three Months Ended June 30, – 2026 – Dollars – (Unaudited)Three Months Ended June 30, – 2026 – Revenue Percentage – (Unaudited)Three Months Ended June 30, – 2025 – Dollars – (Unaudited)Three Months Ended June 30, – 2025 – Revenue Percentage – (Unaudited)
Net (loss) income from continuing operations-144,106-19.5%5,3810.8%
Interest expense, net26,2093.5%27,5334.2%
Income tax (benefit) expense-21,227-2.9%32,7805.0%
Depreciation and amortization, including patient equipment depreciation114,76615.6%86,92513.2%
EBITDA-24,358-3.3%152,61923.2%
Equity-based compensation expense (a)5,3980.7%6,0100.9%
Gain on sale of businesses (b)-6,269-0.8%-32,225-4.9%
Restructuring expenses (c)6,0700.7%—%
Loss on extinguishment of debt (d)1,3220.2%—%
Goodwill impairment (e)144,23619.5%—%
Other non-recurring expenses, net (f)5,5940.8%10,0151.6%
Adjusted EBITDA131,99317.8%136,41920.8%
Adjusted EBITDA Margin17.8%20.8%

Income Statement

Six Months Ended June 30, (in thousands, except percentages)

Six Months Ended June 30, – 2026 – Dollars – (Unaudited)Six Months Ended June 30, – 2026 – Revenue Percentage – (Unaudited)Six Months Ended June 30, – 2025 – Dollars – (Unaudited)Six Months Ended June 30, – 2025 – Revenue Percentage – (Unaudited)
Net loss from continuing operations-167,956-11.8%-7,121-0.5%
Interest expense, net51,8033.6%55,9324.3%
Income tax (benefit) expense-28,392-2.0%30,2942.3%
Depreciation and amortization, including patient equipment depreciation215,68315.2%175,86613.5%
EBITDA71,1385.0%254,97119.6%
Equity-based compensation expense (a)11,7640.8%11,2020.9%
Litigation settlement expense (b)500—%—%
Gain on sale of businesses (c)-6,269-0.4%-32,225-2.5%
Restructuring expenses (d)6,0700.4%—%
Loss on extinguishment of debt (e)1,3220.1%—%
Goodwill impairment (f)144,23610.2%—%
Other non-recurring expenses, net (g)7,7970.6%15,1411.1%
Adjusted EBITDA236,55816.7%249,08919.1%
Adjusted EBITDA Margin16.7%19.1%

Balance Sheet

June 30, 2026 — Condensed Consolidated Balance Sheets (Unaudited) (in thousands)

June 30, 2026December 31, 2025
Cash43,289106,136
Accounts receivable390,389370,897
Inventory105,480114,893
Prepaid and other current assets90,219100,619
Current assets held for sale - discontinued operations168,09836,354
Total current assets797,475728,899
Equipment and other fixed assets, net656,368503,193
Operating lease right-of-use assets127,204111,968
Finance lease right-of-use assets44,80152,300
Goodwill2,370,4312,457,627
Identifiable intangible assets, net31,78035,774
Deferred income taxes, net290,720267,786
Other assets22,09019,119
Noncurrent assets held for sale - discontinued operations139,911
Total Assets4,340,8694,316,577
Current liabilities:Accounts payable and accrued expenses576,300553,700

Cash Flow

Six Months Ended June 30, — Consolidated Statements of Cash Flows (Unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net (loss) income-147,5929,749
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Depreciation and amortization, including patient equipment depreciation226,766186,705
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Goodwill impairment144,236
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Equity-based compensation12,08911,427
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Reduction in the carrying amount of operating lease right-of-use assets21,29915,300
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Reduction in the carrying amount of finance lease right-of-use assets10,0817,096
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Deferred income tax (benefit) expense-21,14712,643
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Loss on extinguishment of debt1,322
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Amortization of deferred financing costs2,3263,105
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Write-off of fixed assets1,178
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Gain on sale of businesses-6,269-32,225
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Other-787
Changes in operating assets and liabilities, net of effects from acquisitions:Accounts receivable-19,4918,868
Changes in operating assets and liabilities, net of effects from acquisitions:Inventory12,066-9,713
Changes in operating assets and liabilities, net of effects from acquisitions:Prepaid and other assets10,045-4,578
Changes in operating assets and liabilities, net of effects from acquisitions:Operating lease obligations-20,351-15,812
Changes in operating assets and liabilities, net of effects from acquisitions:Operating liabilities13,25364,956
Changes in operating assets and liabilities, net of effects from acquisitions:Net cash provided by operating activities239,024257,521
Cash flows from investing activities:Purchases of equipment and other fixed assets-287,456-184,250
Cash flows from investing activities:Payments for business acquisitions, net of cash acquired-127,422-18,561
Cash flows from investing activities:Proceeds from the sale of businesses, net of cash disposed6,269115,674
Cash flows from investing activities:Proceeds from the sale of assets1,439
Cash flows from investing activities:Receipt of contingent consideration from the sale of assets1,156
Cash flows from investing activities:Net cash used in investing activities-407,170-85,981
Cash flows from financing activities:Proceeds from borrowings on long-term debt and lines of credit575,000
Cash flows from financing activities:Repayments on long-term debt and lines of credit-425,000-175,000
Cash flows from financing activities:Repayments of finance lease obligations-8,118-8,346
Cash flows from financing activities:Proceeds received in connection with employee stock purchase plan951564
Cash flows from financing activities:Payments relating to the Tax Receivable Agreement-26,846-25,012
Cash flows from financing activities:Payments of debt financing costs-5,038
Cash flows from financing activities:Distributions to noncontrolling interests-2,349-2,573
Cash flows from financing activities:Payments for tax withholdings from vesting of restricted stock units and stock option exercises-3,090-2,079
Cash flows from financing activities:Payments of deferred purchase price from acquisitions-211-211
Cash flows from financing activities:Net cash provided by (used in) financing activities105,299-212,657
Cash flows from financing activities:Net decrease in cash-62,847-41,117
Cash flows from financing activities:Cash at beginning of period106,136109,747
Cash flows from financing activities:Cash at end of period43,28968,630
Full release

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations and the Company’s acquisition pipeline. These statements are based on various assumptions and on the current expectations of AdaptHealth management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company.

These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which the Company may become a party or governmental investigations to which the Company may become subject that could interrupt or limit the Company’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in the Company’s customers’ preferences, prospects and the competitive conditions prevailing in the healthcare sector. A further description of such risks and uncertainties can be found in the Company’s filings with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently knows or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Use of Non-GAAP Financial Information and Financial Guidance

The Company uses EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, free cash flow and organic revenue, which are financial measures that are not in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, to analyze its financial results and believes that they are useful to investors, as a supplement to U.S. GAAP measures. In addition, the Company’s ability to incur additional indebtedness and make investments under its existing credit agreement is governed, in part, by its ability to satisfy tests based on a variation of Adjusted EBITDA.... (truncated)rrangements.

-3 -

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin should not be considered as measures of financial performance under U.S. GAAP, and the items excluded from EBITDA and Adjusted EBITDA are significant components in understanding and assessing financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of the Company’s liquidity.

The Company uses free cash flow, which is a financial measure that is not in accordance with U.S. GAAP, in its operational and financial decision-making and believes free cash flow is useful to investors because similar measures are frequently used by securities analysts, investors, ratings agencies and other interested parties to evaluate the Company's competitors and to measure the ability of companies to service their debt. The Company's presentation of free cash flow should not be construed as a measure of liquidity or discretionary cash available to the Company to fund its cash needs, including investing in the growth of its business and meeting its obligations.

Free cash flow should not be considered as a measure of financial performance under U.S. GAAP. Accordingly, this key business metric has limitations as an analytical tool. It should not be considered as an alternative to any performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of the Company’s liquidity.

The Company uses organic revenue, which is a financial measure that is not in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, to analyze its financial results and believes that it is useful to investors, as a supplement to U.S. GAAP measures. The change in net revenue from organic revenue is reported as organic revenue as a percentage of prior period total reported net revenue. Management believes organic revenue is meaningful to investors as it provides appropriate visibility into how the Company changes organically—that is, within its existing operations using its own resources.

Organic revenue is defined as all changes in reported net revenues from the comparable period presented, excluding: (1) increases in net revenue in the current period from acquisitions attributable to businesses and/or assets the Company has owned for less than one year based on the month of acquisition. This excludes the acquisition of assets from previous providers to facilitate the transition of patients related to newly awarded at-risk capitated contracts, since the revenue related to these agreements is earned organically; and (2) decreases in net revenue from dispositions existing in the prior period from divested product lines, services, and/or businesses for which there is no revenue recognized in the current period.

This release contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company’s non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results.

In addition, the Company’s financial guidance in this release excludes the impact of any potential additional future strategic acquisitions and any items that have not yet been identified and quantified. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

-4 -

ADAPTHEALTH CORP.

Condensed Consolidated Balance Sheets (Unaudited)

-5 -

ADAPTHEALTH CORP.

Consolidated Statements of Operations (Unaudited)

-6 -

ADAPTHEALTH CORP.

Consolidated Statements of Cash Flows (Unaudited)

-7 -

ADAPTHEALTH CORP.

Non-GAAP Financial Measures

EBITDA and Adjusted EBITDA

This press release presents AdaptHealth’s EBITDA and Adjusted EBITDA for the three and six months ended June 30, 2026 and 2025.

AdaptHealth defines EBITDA as net income (loss) from continuing operations, plus interest expense, net, income tax expense (benefit), and depreciation and amortization, including patient depreciation.

AdaptHealth defines Adjusted EBITDA as EBITDA (as defined above), plus equity-based compensation expense, litigation settlement expense, gain on sale of businesses, restructuring expenses, loss on extinguishment of debt, goodwill impairment, and certain other non-recurring items of expense or income.

The following unaudited table presents the reconciliation of net income (loss) from continuing operations to EBITDA and Adjusted EBITDA, and the reconciliation of net income (loss) from continuing operations as a percentage of net revenue to Adjusted EBITDA Margin, for the three months ended June 30, 2026 and 2025:

-8 -

ADAPTHEALTH CORP.... (truncated):

-9 -

ADAPTHEALTH CORP.

-10 -

ADAPTHEALTH CORP.

Free Cash Flow

This press release presents AdaptHealth’s free cash flow for the three and six months ended June 30, 2026 and 2025.

AdaptHealth defines free cash flow as net cash provided by operating activities less cash paid for purchases of equipment and other fixed assets.

The following unaudited table reconciles net cash provided by operating activities to free cash flow for the three and six months ended June 30, 2026 and 2025:

Contacts

AdaptHealth Corp.

Jason Clemens, CFA

Chief Financial Officer

Luke Montgomery, CFA

Senior Vice President, Investor Relations

IR@adapthealth.com

-11 -

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · AdaptHealth earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.